We are live on ! Find out more
PRVB

Provention Bio, Inc. Common Stock
PRVB

Delisted

PRVB was delisted on the 26th of April, 2023.

Back to rankings

100 hedge funds and large institutions have $284M invested in Provention Bio, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 47 increasing their positions, 28 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

156% more call options, than puts

Call options by funds: $5.1M | Put options by funds: $1.99M

68% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 28

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

4% less capital invested

Capital invested by funds: $294M → $284M (-$10.5M)

6% less funds holding

Funds holding: 106 → 100 (-6)

38% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 16

Holders
100
Holders Change
-6
Holders Change %
-5.66%
% of All Funds
2.02%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
10
Increased
47
Reduced
28
Closed
16
Calls
$5.1M
Puts
$1.99M
Net Calls
+$3.11M
Net Calls Change
-$3.66M

Top Buyers

Rank Fund Capital Flow
1
GGHC
Gilder Gagnon Howe & Co
New York
+$11.4M
2
Two Sigma Advisers
Two Sigma Advisers
New York
+$6.03M
3
BlackRock
BlackRock
New York
+$5.41M
4
Northern Trust
Northern Trust
Illinois
+$4.8M
5
Two Sigma Investments
Two Sigma Investments
New York
+$4.8M

Top Sellers

Rank Fund Capital Flow
1
Citigroup
Citigroup
New York
-$7.22M
2
JJIJ
Johnson & Johnson Innovation - JJDC
New Jersey
-$6.95M
3
Millennium Management
Millennium Management
New York
-$5.87M
4
MIM
Monashee Investment Management
Massachusetts
-$3.53M
5
PA
Perceptive Advisors
New York
-$3.28M
Name Holding Trade Value Shares
Change 		Change in
Stake
PA
1
Perceptive Advisors
New York
$54.7M -$3.28M -260,000 -6%
BlackRock
2
BlackRock
New York
$42.5M +$5.41M +428,534 +15%
Vanguard Group
3
Vanguard Group
Pennsylvania
$28.2M +$852K +67,428 +3%
GGHC
4
Gilder Gagnon Howe & Co
New York
$27.6M +$11.4M +900,142 +72%
State Street
5
State Street
Massachusetts
$13.3M +$2.12M +167,640 +19%
6CM
6
683 Capital Management
New York
$11M +$3.28M +259,314 +43%
Geode Capital Management
7
Geode Capital Management
Massachusetts
$8.23M +$1.11M +87,571 +16%
Northern Trust
8
Northern Trust
Illinois
$7.58M +$4.8M +380,366 +181%
JJIJ
9
Johnson & Johnson Innovation - JJDC
New Jersey
$7.38M -$6.95M -550,000 -49%
Two Sigma Advisers
10
Two Sigma Advisers
New York
$7.09M +$6.03M +477,500 +635%
Two Sigma Investments
11
Two Sigma Investments
New York
$7.06M +$4.8M +379,956 +223%
MWNA
12
Marshall Wace North America
New York
$6.4M +$327K +25,889 +5%
DCM
13
DG Capital Management
New York
$5.35M +$1.64M +129,920 +45%
N
14
Nuveen
North Carolina
$4.8M +$2.62M +207,787 +125%
Invesco
15
Invesco
Georgia
$4.65M -$744K -58,916 -14%
Charles Schwab
16
Charles Schwab
California
$4.04M +$2.68M +212,320 +208%
RHJA
17
Rice Hall James & Associates
California
$2.96M +$1.07M +84,917 +58%
Bank of New York Mellon
18
Bank of New York Mellon
New York
$2.2M +$131K +10,344 +6%
SG Americas Securities
19
SG Americas Securities
New York
$2.01M +$1.24M +98,405 +170%
Susquehanna International Group
20
Susquehanna International Group
Pennsylvania
$1.99M +$464K +36,748 +31%
PI
21
Putnam Investments
Massachusetts
$1.88M +$117K +9,288 +7%
SCM
22
Soleus Capital Management
Connecticut
$1.79M +$1M +79,518 +133%
Goldman Sachs
23
Goldman Sachs
New York
$1.72M +$345K +27,302 +26%
Victory Capital Management
24
Victory Capital Management
Texas
$1.71M -$37.4K -2,958 -2%
Truist Financial
25
Truist Financial
North Carolina
$1.59M +$126K +10,000 +9%
1
2 3 4 5

PRVB Hedge Fund Activity: Q3 2020 in Review

100 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Provention Bio, Inc. Common Stock (PRVB) for Q3 2020, worth a combined $284M — down 3.6% from $294M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of PRVB and 10 opened new positions — a net loss of 6 holders — while 28 trimmed existing stakes and 47 added.

The largest buyer was Gilder Gagnon Howe & Co, adding an estimated $11.4M. The largest seller was Citigroup, cutting an estimated $7.22M.

  • 100 institutional investors held Provention Bio, Inc. Common Stock (PRVB) as of Q3 2020, down from 106 in Q2 2020.
  • Funds reported $284M of Provention Bio, Inc. Common Stock stock for Q3 2020, down 3.6% quarter-over-quarter.
  • 10 funds opened new Provention Bio, Inc. Common Stock positions in Q3 2020 and 16 closed out, a net change of -6 holders.
  • The largest Provention Bio, Inc. Common Stock buyer in Q3 2020 was Gilder Gagnon Howe & Co, an estimated $11.4M added.
  • The largest Provention Bio, Inc. Common Stock seller in Q3 2020 was Citigroup, an estimated $7.22M sold.

Based on aggregated 13F filings for Q3 2020.